Little RNA can better your heart functioning: LncRNA Mirt2 -based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: LncRNA Mirt2 (Myocardial infarction-associated transcript 1 (Mirt1) increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes, via up-regulation of its target gene, 10/July/2019, 11.41 am

Natural product-based Lifespan extension therapy:  Polysaccharides, derived from Lycium barbarum L (LBL),  inhibit the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extend mammalian lifespan by regulating the expression of their target genes, 10/July/2019, 10.15 am
July 10, 2019
Mechanistic insights into how Methylprednisolone(MPD) may function as a pain medication: Methylprednisolone(MPD),  used in the treatment of rheumatic disorders, asthma, allergies and others,  increases the expression of PD-L1, decreases the expression of Cox-2, attenuates acutes and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability, via up-regulation of its target gene, 12/July/2019, 10.26 pm
July 12, 2019
Show all

Introduction: What they say

A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was published, in the 6 April  2015 issue of the journal “Nature cell biology” (the number 1 journal in “Cell biology” research with an impact factor of 20+)by Prof Tzahor E, D’Uva E, and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Little RNA can better your heart functioning: LncRNA Mirt2 -based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: LncRNA Mirt2 (Myocardial infarction-associated transcript 1 (Mirt1) increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes, via up-regulation of its target gene


From the significance of the study to Public health relevance: 

Given that: (1)  cardiovascular disease is the leading cause of death worldwide; (2) the raise of death rate, due to cardiovascular disease, has increased from  123 lakhs in 1990 to 173 lakhs in 2013; (3) 85% of people over 80 years are susceptible to cardiovascular diseases;(4) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (3) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; (4) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (5) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year by 2030, there is an urgent need to find: (i) a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs and (iv) a side-effect-free Natural product-based drug.

 


From research findings to Therapeutic opportunity: 

This study provides, for the first time, mechanistic insights into how LncRNA Mirt2 (Myocardial infarction-associated transcript 1 (Mirt1) may aid in heart regeneration and repair.

LncRNA Mirt2, by regulating the expression of its target genes, it may: (1) increase ERBB2/Her2 expression; (2) induce cardiomyocyte (CM) dedifferentiation and proliferation; and (3) cardiomyocyte (CM) redifferentiation and regeneration (fig.1).  Thus, pharmacological formulations encompassingLncRNA Mirt2 or its activators, either alone or in combination with other drugs,” may be used to promote cardiac dedifferentiation and regeneration.

Figure1. Mechanistic insights into how LncRNA Mirt2 may promote cardiac dedifferentiation and regeneration. LncRNA Mirt2, by regulating the expression of its target genes, it may upregulate the expression of ERRB2/HER2 and promote cardiac dedifferentiation and regeneration

Figure 2. LncRNA Mirt2 may promote cardiac regeneration through induction of Her2/Erbb2

Figure 3. While it had been shown that  genetic ablation or pharmacological action of of Her2/ERBB2 inhibits cardiomyocyte proliferation and promotes dedifferentiation and proliferation followed by redifferentiation and regeneration, respectively, the study presented here suggests that activation or induction or injection of LncRNA Mirt2 may promote cardiomyocyte proliferation and regeneration after myocardial infarction.  

Given the mechanistic basis of how LncRNA Mirt2 or its activators may aid in cardiomyocyte survival and regeneration,  medical practitioners and cardiologists may consider treating myocardial patients with LncRNA Mirt2 or its activator(s) or its inducer(s), as it may aid in cardiomyocyte regeneration following myocardial infarction


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:  Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $ 500#

Undisclosed (mechanistic insights) information: How does  LncRNA Mirt2 increase the expression of  ERBB2/Her2?

For purchase and payment details, you may reach us at admin@genomediscovery.org

# Research cooperation


References: 

Web: http://genomediscovery.org or newbioideas.com

Citation: Boominathan, L.,  Little RNA can better your heart functioning: LncRNA Mirt2 -based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: LncRNA Mirt2 (Myocardial infarction-associated transcript 1 (Mirt1) increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes, via up-regulation of its target gene, 10/July/2019, 11.40 am,  Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

Comments are closed.